Durvalumab not cost-effective with current pricing strategies for stage III NSCLC: The drug remains inaccessible to many patients for whom it is indicated as a standard of care after chemoradiation.
作者信息
Nierengarten Mary Beth
出版信息
Cancer. 2024 Oct 1;130(19):3236. doi: 10.1002/cncr.35529.
PMID:39226077
Abstract
摘要
Zotero 插件